Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Expression of the CXC chemokine receptor 3 and its ligands in ischemia-reperfusion injury of liver in rats.

Authors: Liu, Z  Xu, W  Zhang, X  Cui, D  Liu, B 
Citation: Liu Z, etal., Transplant Proc. 2008 Jun;40(5):1300-2.
Pubmed: (View Article at PubMed) PMID:18589091
DOI: Full-text: DOI:10.1016/j.transproceed.2007.11.076

OBJECTIVE: To explore the expression of the CXC chemokine receptor 3 (CXCR3) and its ligands (IP-10, Mig) in ischemiareperfusion (I/R) injury of rat livers. METHODS: Thirty-two Wistar rats were randomly divided into four groups with eight rats in each group: sham operation (SO) and 6-, 12-, or 24-hour I/R groups. The levels of tumor necrosis factor-alpha (TNF-alpha) in liver tissues were measured by enzyme-linked immunosorbent assay. The expressions of CXCR3 and its ligands (IP-10, Mig) were detected by semiquantitative reverse-transcriptase polymerase chain reaction. The serum levels of alanine transferase and aspartate transferase were also measured. RESULTS: Low expressions of CXCR3, IP-10, and Mig mRNA were determined in the SO group. The expressions of CXCR3 and IP-10 mRNA in the ischemic tissue of the I/R group were significantly greater than those in the SO group (P < .01). The expressions of CXCR3 and IP-10 mRNA of the ischemic tissue in the 6-hour I/R group were higher than those in the 12-hour I/R group (P < .01). There was no difference in the levels of Mig mRNA between the I/R and SO groups. Compared with the SO group, the level of TNF-alpha was significantly increased in the I/R group, reaching its peak at reperfusion 12 hour. CONCLUSION: The mRNA expressions of CXCR3 and its ligand IP-10 were up-regulated in liver I/R tissue in the early time, which suggested that they play an important role in liver injury induced by I/R.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 2311376
Created: 2009-07-09
Species: All species
Last Modified: 2009-07-09
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.